Brief: EMA's CHMP Recommends Extension Of Therapeutic Indication For Pfizer's Hympavzi
27/03/2026 11:56
March 27 (Reuters) - EMA's CHMP: EMA'S CHMP: RECOMMENDED GRANTING MARKETING AUTHORISATION FOR IMDYLLTRA (TARLATAMAB) FOR TREATMENT OF RELAPSED EXTENSIVE-STAGE SMALL CELL LUNG CANCER EMA'S CHMP: CONFIRMED RECOMMENDATION TO REFUSE A CHANGE TO MARKETING AUTHORISATION FOR HETLIOZ (TASIMELTEON) EMA'S CHMP: CONFIRMED ITS RECOMMENDATION TO REFUSE A CHANGE TO THE MARKETING AUTHORISATION FOR HETLIOZ (TASIMELTEON) EMA'S CHMP: JOENJA (LENIOLISIB) RECEIVED POSITIVE OPINION FOR MARKETING AUTHORISATION UNDER EXCEPTIONAL CIRCUMSTANCES EMA'S CHMP: APPLICATION FOR INITIAL MARKETING AUTHORISATION OF BLARCAMESINE ANAVEX WAS WITHDRAWN. EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR HYMPAVZI Further company coverage: AMGN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharming NV
See all newsPharming shares plunge on declining Ruconest sales
Netherlands' Pharming Group prelim Q1 revenue falls on lower RUCONEST sales
Brief: Pharming Group Q1 Net Income USD -5.2 Million
Brief: EMA's CHMP Recommends Extension Of Therapeutic Indication For Pfizer's Hympavzi
Brief: Pharming Group NV Receives Positive CHMP Opinion for Joenja